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Abstract
Background: Patient recruitment in clinical trials is often challenging, and as a result, many trials are stopped early
due to insufficient recruitment. The re-randomization design allows patients to be re-enrolled and re-randomized
for each new treatment episode that they experience. Because it allows multiple enrollments for each patient, this
design has been proposed as a way to increase the recruitment rate in clinical trials. However, it is unknown to
what extent recruitment could be increased in practice.
Methods: We modelled the expected recruitment rate for parallel-group and re-randomization trials in different
settings based on estimates from real trials and datasets. We considered three clinical areas: in vitro fertilization,
severe asthma exacerbations, and acute sickle cell pain crises. We compared the two designs in terms of the
expected time to complete recruitment, and the sample size recruited over a fixed recruitment period.
Results: Across the different scenarios we considered, we estimated that re-randomization could reduce the
expected time to complete recruitment by between 4 and 22 months (relative reductions of 19% and 45%), or
increase the sample size recruited over a fixed recruitment period by between 29% and 171%. Re-randomization
can increase recruitment most for trials with a short follow-up period, a long trial recruitment duration, and patients
with high rates of treatment episodes.
Conclusions: Re-randomization has the potential to increase the recruitment rate in certain settings, and could
lead to quicker and more efficient trials in these scenarios.
Keywords: Re-randomization, Randomized controlled trials, Recruitment, Efficient trial design
Background
Recruitment to randomized controlled trials (RCTs) is
challenging, and many trials are either stopped early due
to insufficient recruitment, or require longer to complete
than expected [1–5]. This can have adverse impacts on
patient care. Trials which are terminated early will be
underpowered, and may not produce high-quality evi-
dence. Poor recruitment can make conducting trials in
certain areas infeasible; this can be particularly problem-
atic for trials in rare diseases [6, 7]. Poor recruitment
can also lead to concerns regarding the ethics of ex-
posing participants to the potential harms of taking
part in the trial and then failing to use their contribution if
recruitment proves infeasible. Longer recruitment periods
are also problematic, as they lead to higher costs, allowing
fewer trials overall to be funded. Furthermore, longer re-
cruitment periods will delay trial results being known,
leading to delays in successful interventions being adopted
into routine care, or in unsuccessful or harmful treatments
being discontinued. Poor recruitment is a major barrier to
conducting effective RCTs, and has been identified as
the top research priority for leads of UK Clinical Trials
Units [8].
The re-randomization design has been proposed as a
way of increasing the recruitment rate compared to par-
allel-group trials [9]. The re-randomization design in-
volves re-enrolling and re-randomizing patients who
require further treatment after their initial enrollment
is complete. An overview of this design is provided in
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Table 1, and further details are available in a previous
publication [9]. The re-randomization design can be used
in situations where (1) patients may require treatment on
multiple occasions, (2) the intervention(s) under study
would be used for each new treatment episode, and (3)
the intervention duration and length of the follow-up
period for each randomization are less than the overall
length of the trial recruitment period.
Re-randomization trials can provide unbiased estimates
of treatment effect and correct type I error rates provided:
(1) patients are only re-enrolled and re-randomized after
the follow-up period from their previous treatment epi-
sode is complete, and (2) randomizations for the same pa-
tient are performed independently [9]. It is important to
note that the number of times that each patient is enrolled
is not specified in advance, and instead depends on the
number of treatment episodes that they experience during
the course of the trial. For example, some patients may be
enrolled once; others may be enrolled multiple times.
Then, under the assumption that the treatment effect
is constant (i.e. that the intervention confers the same
benefit relative to control across all patients and all
treatment episodes), and that the variance of the out-
come is the same under re-randomization as it would be
in a parallel-group design (i.e. that the variance is not in-
creased in a re-randomization trial), re-randomization
will have the same power as a parallel-group trial with
an equivalent number of observations [9]. This result is
independent of intraclass correlation coefficient (i.e. the
degree of correlation between treatment episodes from
the same patient); full details are available in a previous
publication [9].
This implies that when the above assumptions are
reasonable, the same sample size calculation as in a
parallel-group design could be used, but instead of
recruiting the specified number of patients, a re-
randomization trial could recruit the specified number
of treatment episodes. For example, instead of recruiting
200 individual patients, the re-randomization design
would recruit 200 treatment episodes. Because some
patients will contribute multiple treatment episodes,
this will increase the recruitment rate compared to a
parallel-group trial, thereby allowing re-randomization
trials to be conducted more quickly. In scenarios where
the above assumptions are not likely, re-randomization
could still be used, provided it meets the criteria out-
lined in Table 1. However, a larger number of treatment
episodes may be required, although in some cases this
would still require fewer overall patients than a parallel-
group design, and so would still facilitate quicker
recruitment.
Despite the potential advantages of the re-randomization
design in terms of increased recruitment rate, there has
been little previous research on its potential impact, and it
is, therefore, unknown how much of an effect on recruit-
ment it might have in practice. We therefore conducted a
modelling study to assess the impact that re-randomization
could have on recruitment in three different clinical areas:
(1) in vitro fertilization (IVF), (2) severe asthma exacerba-
tions, and (3) acute sickle cell pain crises.
Methods
We begin by examining some of the factors that will in-
fluence how much of an advantage re-randomization
can provide. Over a fixed recruitment duration, the in-
creased recruitment from a re-randomization trial versus
a parallel-group trial can be measured by:
Number enrolled treatment episodes
Number enrolled patients
i.e. it measures the number of extra treatment episodes
that we would recruit through re-randomization as com-
pared to a parallel-group design.
The number of extra enrolled treatment episodes is
determined by (1) the total number of treatment epi-
sodes that occur during the trial recruitment period and
(2) the proportion of these treatment episodes that are
enrolled in the trial.
Some of the key factors that can affect (1) and (2)
above (and thus determine the recruitment benefit con-
ferred through re-randomization) are:
Table 1 Overview of re-randomization trials
Setting requirements for re-randomization trials 1) Some patients may require treatment on multiple occasions
2) The intervention(s) would be used for each new treatment episode
3) The intervention duration and length of the follow-up period for each treatment episode are
less than the overall length of the trial recruitment period
Design requirements for re-randomization trials 1) Patients are only re-enrolled and re-randomized when they have completed the follow-up
period from their previous randomization
2) Randomizations for the same patient are performed independently
Implementation of re-randomization trials 1) Patients are enrolled as usual, randomized to a treatment group, and followed-up until all
outcomes have been collected
2) If patients experience new treatment episodes and require further treatment, they can be
re-enrolled and re-randomized, provided they have completed the follow-up period from their
previous randomization
3) This process is repeated until the target sample size is met
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 The rate of treatment episodes: higher rates lead to
higher numbers of treatment episodes
 The length of the recruitment period: longer
recruitment periods will lead to higher numbers of
treatment episodes
 The recruitment trajectory of new patients: if most
new patients are recruited towards the end of the
trial, this could lead to lower numbers of treatment
episodes compared to a constant recruitment
trajectory (as there would be less time for patients
recruited towards the end of the trial to experience
new treatment episodes)
 The length of the follow-up period: because we
cannot enroll patients until the follow-up period
from their previous enrollment is complete, shorter
follow-up periods will lead to larger proportions of
treatment episodes that can be enrolled in the trial
 Limits on the number of enrollments per patient:
lower limits will lead to lower proportions of
treatment episodes that are enrolled
 The probability of patient’s re-consenting for
re-enrollment: lower numbers of patients who
re-consent to re-enroll for their 2nd, 3rd, 4th, etc.,
treatment episode will lead to a lower proportion of
treatment episodes that are enrolled
From this, we can see that re-randomization trials will
increase recruitment the most when there is a short
follow-up period, a long trial recruitment period, and pa-
tients have a high rate of treatment episodes. Instituting
small limits on the number of enrollments allowed per
patient will reduce the benefit from re-randomization, as
will low rates of re-consent from patients for subsequent
treatment episodes.
Modelling study
We modelled the expected recruitment rates for parallel-
group and re-randomization designs across three clinical
areas. For each clinical area, we considered several sce-
narios based on different sample size targets and different
recruitment durations for a parallel-group design. We
considered both small and large sample size targets and
short and long recruitment durations. This led to four
unique scenarios for each clinical area: (1) small sample
size, short recruitment duration, (2) small sample size, long
recruitment duration, (3) large sample size, short recruit-
ment duration, and (4) large sample size, long recruitment
duration.
Within each of the three clinical scenarios, we selected
two published or ongoing trials on which to base the
sample size targets and recruitment durations (exact
values listed below). There was no formal or systematic
process for identifying or selecting potential trials; instead,
we considered any trials we were aware of, provided they
would have been appropriate for a re-randomization
design. We selected two trials for each clinical area on
the basis that the trials provided diverse sample sizes
and recruitment durations.
To model recruitment from a parallel-group trial, we
assumed a constant recruitment rate throughout the
recruitment period. We calculated the monthly recruit-
ment rate by dividing the target sample size by the total
recruitment duration (in months).
To model the recruitment rate for re-randomization
trials, we assumed that the same number of new patients
(not previously enrolled in the trial) would be recruited
each month as in a parallel-group design. We therefore
used the same monthly recruitment rate for new patients
as for a parallel-group trial. We then assumed that a cer-
tain proportion of newly recruited patients would be re-
randomized during the remainder of the recruitment
period. These proportions were estimated from published
studies, and are listed below. We estimated the total re-
cruitment in each month for re-randomization trials by
adding the number of newly enrolled patients and the
number of re-randomized patients together.
We then estimated the cumulative recruitment for both
parallel-group and re-randomization trials. We compared
recruitment between the two different designs in two
ways; (1) the time to complete recruitment and (2) the
sample size recruited over a fixed time period. We calcu-
lated the time to complete recruitment as the month in
which the cumulative recruitment passed the sample size
target (note that that the time to complete recruitment for
parallel-group designs was set to be equal to the recruit-
ment duration discussed earlier). We calculated the
sample size recruited over a fixed time period as the
cumulative recruitment at the end of the specified re-
cruitment duration for the parallel-group trial (i.e. we
estimated what the cumulative recruitment for a re-
randomization trial would have been if it had continued
to recruit over the same time frame as the parallel-
group trial).
For re-randomization trials, we instituted limits on the
number of times that each patient could be enrolled [9].
We used two limits: (1) a smaller number of enrollments
and (2) a larger number of enrollments. The exact values
we used for the limits are listed below.
We provide further details on the assumptions made
for each of the three clinical areas below.
In vitro fertilization
IVF is a technique to help people or couples with fertility
problems become pregnant. Some trials comparing differ-
ent methods of IVF may be suitable for re-randomization
(Table 2), because: (1) some participants who do not
become pregnant after their first IVF cycle may undergo
further cycles [10], (2) some interventions in this area are
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designed to be used for each new cycle, and (3) the dur-
ation of these interventions is often short-term (e.g. during
the cycle), and follow-up is often complete once it is deter-
mined that a cycle was unsuccessful.
We chose two trials as the basis for our modelling
study. The first trial compared minimal stimulation in
IVF to standard IVF [11]. The sample size was 564 partici-
pants, and the recruitment duration was 55 months. The
second trial compared a new method of sperm selection
to the standard method (http://www.habselect.org.uk/).
The trial is not yet complete; the anticipated sample size is
3730 couples, and the anticipated recruitment duration is
21 months. Based on these two trials, we used small and
large sample sizes of 564 and 3730, respectively, and short
and long recruitment durations of 21 and 55 months,
respectively.
We note that because the second trial is not yet
complete, the final sample size and/or the recruitment
duration may differ to what we have assumed here; if the
true recruitment duration is longer than that assumed
here, then our results will underestimate the benefit of re-
randomization (and vice versa).
For re-randomization trials we set the smaller and lar-
ger limit on the number of enrollments for each patient
as two and three IVF cycles, respectively. For a limit of
two IVF cycles, we estimated that 60% of participants
would undergo one cycle that and 40% would undergo
two [12]. For a limit of three IVF cycles, we estimated
that 60% of participants would undergo one cycle, 25%
would undergo two cycles and that 15% would undergo
three cycles [12]. We set a 6-month waiting period be-
tween IVF cycles, as this is recommending by some clin-
ical commissioning groups in the UK. We note that this
policy may not be typical for all trials, and as such, our re-
sults may underestimate the benefit of re-randomization.
We calculated the number of re-randomized treatment
episodes each month using the following steps. First we
modelled the number new enrollments each month
using the same approach as for parallel-group trials. We
then calculated the expected number of IVF cycles that
would occur each month for patients who had previously
been enrolled (accounting for the limit on the number of
times each patient was allowed to be enrolled). The
monthly recruitment rate under re-randomization was
then calculated by adding the number of new enrollments
each month to the number of re-randomizations that oc-
curred each month. Further details on these calculations
are available in the Appendix.
Severe asthma exacerbations
People with asthma sometimes experience severe asthma
exacerbations which may require treatment in hospital.
Some trials comparing different methods of treating severe
asthma exacerbations may be suitable for re-randomization
(Table 2), because: (1) some people may experience more
than one exacerbation during a given time period [13], (2)
Table 2 Suitability of re-randomization in the setting of (1) in vitro fertilization, (2) severe asthma exacerbations, and (3) acute sickle
cell pain crises
Clinical area Setting requirement Justification
In vitro fertilization 1) Some patients may require treatment on multiple
occasions
Some participants who do not become pregnant after their
first IVF cycle may undergo further cycles
2) The intervention(s) would be used for each new
treatment episode
The interventions considered (minimal stimulation, sperm
selection) are designed to be used for each new cycle
3) The intervention duration and length of the follow-up
period for each treatment episode are less than the overall
length of the trial recruitment period
The interventions considered (minimal stimulation, sperm
selection) are short-term (during the IVF cycle)
The follow-up period will vary between trials, but will often
be complete once it is determined a cycle was unsuccessful
Severe asthma
exacerbations
1) Some patients may require treatment on multiple
occasions
Some patients may experience more than one exacerbation
during a given time period
2) The intervention(s) would be used for each new
treatment episode
The interventions considered (magnesium sulphate) are
designed to be used for each new exacerbation
3) The intervention duration and length of the follow-up
period for each treatment episode are less than the
overall length of the trial recruitment period
The interventions considered (magnesium sulphate) is short-term,
and given while a patient is experiencing an exacerbation.
The follow-up period will vary between trials, but is often
relatively short-term
Acute sickle cell pain
crises
1) Some patients may require treatment on
multiple occasions
Some patients may experience more than one pain crisis
during a given time period
2) The intervention(s) would be used for each new
treatment episode
The interventions considered (nitric oxide gas, ketoprofen)
are designed to be used for each new pain crisis
3) The intervention duration and length of the follow-up
period for each treatment episode are less than the
overall length of the trial recruitment period
The interventions considered (nitric oxide gas, ketoprofen) is
short-term, and given while a patient is experiencing a pain crisis.
The follow-up period will vary between trials, but is often
relatively short-term
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most interventions to treat exacerbations are designed to
be used for each new exacerbation, and (3) interventions
are often short-term (e.g. while the patient is experiencing
an exacerbation), and length of follow-up is often relatively
short-term.
We chose two trials as the basis for our modelling study.
The first trial compared intravenous and nebulized
magnesium sulphate with placebo [14]. The target sample
size was 1200; however, due to slower than anticipated re-
cruitment the trial stopped early after 1109 patients were
enrolled. The recruitment duration was 47 months. The
second trial also compared nebulized magnesium sulphate
with placebo [15]. The sample size was 508, and the re-
cruitment duration was 27 months. Based on these two
trials, we used small and large sample sizes of 508 and
1200, respectively, and short and long recruitment dura-
tions of 27 months and 47 months, respectively.
For re-randomization trials we set the smaller and larger
limit on the number of enrollments for each patient as
two and four treatment episodes, respectively. We also as-
sumed a 1-month follow-up period, meaning that patients
could not be re-randomized for at least 1 month after their
previous enrollment. We estimated the exacerbation
rate as 0.52/6 months [13], equating to a monthly rate
of 0.087. We assumed that this rate followed a Poisson
distribution.
We calculated the number of re-randomized treatment
episodes each month using the following steps. First we
modelled the number new enrollments each month
using the same approach as for parallel-group trials. We
then calculated the expected number of exacerbations
that newly enrolled patients would have between the
end of their follow-up period and the end of the recruit-
ment period (accounting for the limit on the total num-
ber of times each patient was allowed to be enrolled).
We assumed that on average these exacerbations would
occur uniformly across the remaining months, and that
patients enrolled in the trial once would be enrolled
again for all subsequent exacerbations. The monthly re-
cruitment rate under re-randomization was then calcu-
lated by adding the number of new enrollments each
month to the number of re-randomizations that oc-
curred each month. Further details on these calculations
are available in the Appendix.
Acute sickle cell pain crises
People with sickle cell disease sometimes experience
painful sickle cell crises, which often require hospitalization
for treatment. Some trials comparing different methods
of treating acute sickle cell pain crises may be suitable
for re-randomization (Table 2), because: (1) some people
may experience more than one pain crisis during a given
time period [16], (2) most interventions to treat pain crises
are designed to be used for each new pain crisis, and (3)
interventions are often short-term (e.g. while the patient is
experiencing a pain crisis) and length of follow-up is often
relatively short-term.
We chose two trials as the basis for our modelling
study. The first trial compared inhaled nitric oxide gas
with placebo [17]. The sample size was 150 and the re-
cruitment duration was 49 months. The second trial
compared ketoprofen with placebo [18]. The sample size
was 66 and the recruitment duration was 32 months.
Based on these two trials, we used small and large sam-
ple sizes of 66 and 150, respectively, and short and long
recruitment durations of 32 months and 49 months,
respectively.
For re-randomization trials we set the smaller and lar-
ger limit on the number of enrollments for each patient
as two and four treatment episodes, respectively. We
also assumed a 1-month follow-up period, meaning that
patients could not be re-randomized for at least 1 month
after their previous enrollment. The rate of hospitaliza-
tions for people with sickle cell disease is 1.5/year [16];
however, only 76.9% of hospitalizations were for pain
crises. We therefore estimated the rate of hospitaliza-
tions for acute pain crises as 1.15/year, equating to a rate
of 0.096/month. We assumed that this rate followed a
Poisson distribution.
We calculated the number of re-randomized treatment
episodes each month using the same approach as for
severe asthma exacerbations; full details of these calcu-
lations can be found in the Appendix.
Results
In vitro fertilization
Results are shown in Fig. 1. Compared to a parallel-group
design, re-randomization reduced the expected time to
complete recruitment by between 4 months (17 versus 21
months; 19% relative reduction) and 17 months (38 versus
55 months; 31% relative reduction) across different scenar-
ios. Over a fixed recruitment period, re-randomization in-
creased the sample size by between 29% (726 versus 564)
and 47% (831 versus 564).
Severe asthma exacerbations
Results are shown in Fig. 2. Compared to a parallel-
group design, re-randomization reduced the expected time
to complete recruitment by between 7 months (20 versus
27 months; 26% relative reduction) and 20 months (27 ver-
sus 47 months; 43% relative reduction) across different sce-
narios. Over a fixed recruitment period, re-randomization
increased the sample size by between 56% (795 versus 508)
and 156% (1299 versus 508).
Acute sickle cell pain crises
Results are shown in Fig. 3. Compared to a parallel-group
design, re-randomization reduced the expected time to
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Fig. 1 Comparison of recruitment rates between re-randomization and parallel-group designs in in vitro fertilization (IVF) trials. *PG parallel-group,
RR re-randomization. The red line denotes recruitment for a parallel-group trial. The blue line denotes recruitment for a re-randomization trial where
each participant may be enrolled for a maximum of two treatment cycles. The green line denotes recruitment for a re-randomization design where
each participant may be enrolled for a maximum of three treatment cycles. The dotted line denotes the sample size target. For the re-randomization
designs, treatment cycles were 6 months apart. Panel a denotes a small trial (n = 564) with a short recruitment duration (21 months). Panel b denotes a
small trial (n = 564) with a long recruitment duration (55 months). Panel c denotes a large trial (n = 3730) with a short recruitment duration (21 months).
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Fig. 2 Comparison of recruitment rates between re-randomization and parallel-group designs in trials of asthma exacerbations. *PG parallel-group,
RR re-randomization. The red line denotes recruitment for a parallel-group trial. The blue line denotes recruitment for a re-randomization trial where each
participant may be enrolled for a maximum of two treatment episodes. The green line denotes recruitment for a re-randomization design where each
participant may be enrolled for a maximum of four treatment episodes. The dotted line denotes the sample size target. Panel a denotes a small trial
(n = 508) with a short recruitment duration (27 months). Panel b denotes a small trial (n = 508) with a long recruitment duration (47 months). Panel c
denotes a large trial (n= 1200) with a short recruitment duration (27 months). Panel d denotes a large trial (n = 1200) with a long recruitment duration
(47 months)
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complete recruitment by between 9 months (23 versus 32
months; 28% relative reduction) and 22 months (27 versus
49 months; 45% relative reduction) across different scenar-
ios. Over a fixed recruitment period, re-randomization in-
creased the sample size by between 64% (108 versus 66)
and 171% (179 versus 66).
Discussion
Poor recruitment is a common problem in RCTs, and is
a major barrier to conducting effective trials. In this study
we evaluated the potential impact of re-randomization on
recruitment. We found that it can substantially increase
the recruitment rate in some situations, allowing trials to
be completed more quickly. At the extreme, we estimated
that re-randomization could reduce the recruitment dur-
ation by almost 2 years for a trial of acute sickle cell pain
crises (from 49 to 27 months, a 45% reduction). However,
benefits were not always so large; in one scenario, re-
randomization reduced the recruitment period by only
four months (from 21 to 17 months, a 19% reduction). Al-
ternatively, re-randomization could be used to increase
the sample size compared to a parallel-group design;
we estimated that over a fixed recruitment period, re-
randomization increased the number of treatment epi-
sodes between 29% and 171%.
The potential benefits of re-randomization depend on
several factors, including the rate of treatment episodes,
the length of the follow-up period, and the duration of
the trial recruitment period. Other factors, such as the
recruitment trajectory for new patients, the probability
that patients re-enroll for subsequent treatment episodes,
and whether there are limits on the number of treatment
episodes per patient will also affect the recruitment rate
for re-randomization trials.
Our study had several limitations. We chose the mod-
elling parameters based on real trials and datasets; how-
ever, we used only a limited number of examples. It is
possible that using parameters based on other trials or
datasets may have given different results. We also as-
sumed a constant recruitment trajectory, and assumed
that patients would re-consent for each new treatment
episode during the trial period. These assumptions may
not always be valid in practice, and if violated would lead
to reduced recruitment from re-randomization. However,
we generally opted to use more conservative parameter es-
timates when possible, which may have led to more con-
servative estimates of benefit. For example, we chose the
rate of asthma exacerbations as 1.04/year [13]; however,
other studies have reported rates of up to 3.2/year [19].
We also instituted limits on the number of randomiza-
tions per patient; however, we note that there is as of yet
no consensus on whether limits should be routinely im-
posed in re-randomization trials; for trials that do not limit
the number of randomizations, our results may therefore
underestimate the benefit of re-randomization.
The re-randomization design is a relatively new pro-
posal, and as such, much of the methodology research
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Fig. 3 Comparison of recruitment rates between re-randomization and parallel-group designs in trials of acute sickle cell pain crises.
*PG parallel-group, RR re-randomization. The red line denotes recruitment for a parallel-group trial. The blue line denotes recruitment for a
re-randomization trial where each participant may be enrolled for a maximum of two treatment episodes. The green line denotes recruitment for a
re-randomization design where each participant may be enrolled for a maximum of four treatment episodes. The dotted line denotes the sample size
target. Panel a denotes a small trial (n = 66) with a short recruitment duration (32 months). Panel b denotes a small trial (n = 66) with a long recruitment
duration (49 months). Panel c denotes a large trial (n = 150) with a short recruitment duration (32 months). Panel d denotes a large trial (n = 150) with
a long recruitment duration (49 months)
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analysis of such trials is still ongoing. Further informa-
tion on design and analysis issues for re-randomization
trials are available elsewhere [9, 10, 20].
Although re-randomization can provide benefit in terms
of recruitment, it should only be used in appropriate set-
tings, such as when (1) patients may require treatment on
multiple occasions, (2) the intervention(s) under study
would be used for each new treatment episode, and (3) the
intervention duration and length of the follow-up period
for each randomization are less than the overall length of
the trial recruitment period. Using re-randomization in
other settings (e.g. for interventions which would be used
only once in practice, or situations where re-randomization
would have to occur before the follow-up period from the
previous enrollment is complete) could lead to bias or
inaccurate conclusions.
Conclusion
Re-randomization has the potential to increase the re-
cruitment rate in certain settings, and could lead to
quicker and more efficient trials in these scenarios.
Appendix
Estimating recruitment under re-randomization
In vitro fertilization
We calculated the cumulative recruitment as follows. Let:
 ai = the expected number of new enrollments in the
ith month (where ai is constant across all i)
 bi = the expected number of re-randomizations in
the ith month
 CRm = the cumulative recruitment at the end of
month i =m
Then, for a limit of two enrollments per participant,
we calculated bi as:
bi ¼ 0:4ai−6:
For a limit of three enrollments per participant, we
calculated bi as:
bi ¼ 0:4ai−6 þ 0:15ai−12:




ai þ bið Þ:
Severe asthma exacerbations
We calculated the cumulative recruitment as follows.
Let:
 ai = the expected number of new enrollments in the
ith month (where ai is constant across all i)
 bm = the expected number of re-randomizations in
month i =m
 CRm = the cumulative recruitment at the end of
month i =m
 D = the final month of recruitment (i.e. D = 27 if the
recruitment duration for a parallel-group trial is 27
months)
 ci = for patients who were newly enrolled in month i,
ci represents the expected number of treatment
episodes they will experience during months i + 2 to
D. (Note that we used i + 2 to exclude exacerbations
(exacerbations) that occurred during the 1-month
follow-up period from the patient’s initial enrollment)
Then, for a limit of two enrollments per participant,
we calculated ci as:
ci ¼ aiP X≥1ð Þ;
where X denotes the number of episodes that occur during
months i + 2 to D for any particular patient. We calculated
P(X = x) based on a Poisson distribution with a rate
0.087(D − i − 1).
For a limit of four enrollments per participant, we calcu-
lated ci as:
ci ¼ aiP X ¼ 1ð Þ þ 2aiP X ¼ 2ð Þ þ 3aiP X≥3ð Þ:
We assumed that exacerbations (ci) occurred uniformly
throughout the remaining recruitment period. We then
calculated the expected number of re-randomizations in








We then calculated the expected cumulative recruit-




ai þ bið Þ:
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